• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Aggarwal Vijay

    2/2/22 4:01:33 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care
    Get the next $IDXG alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    AGGARWAL VIJAY

    (Last) (First) (Middle)
    MORRIS CORPORATE CENTER 1, BLDG
    C, 300 INTERPACE PARKWAY

    (Street)
    PARSIPPANY, NJ 07054

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/01/2022
    3. Issuer Name and Ticker or Trading Symbol
    INTERPACE BIOSCIENCES, INC. [ IDXG ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Vijay Aggarwal 02/02/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXG

    DatePrice TargetRatingAnalyst
    11/17/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $IDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Interpace Biosciences downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Interpace Biosciences from Buy to Neutral

      11/17/21 6:16:49 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Interpace Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Interpace Biosciences with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      4/9/21 7:22:39 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • HC Wainwright resumed coverage on Interpace Biosciences with a new price target

      HC Wainwright resumed coverage of Interpace Biosciences with a rating of Buy and set a new price target of $6.00 from $10.00 previously

      1/25/21 8:06:42 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    SEC Filings

    See more
    • SEC Form 10-Q filed by Interpace Biosciences, Inc.

      10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      5/8/25 4:28:33 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      5/8/25 4:25:28 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences, Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      4/30/25 7:31:33 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

       ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million    PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter

      5/8/25 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

      Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS) delayed implementation by 60 days earlier in the year and confirmed finalization of the LCD as of today, April 24, 2025. PancraGEN is a DNA-based diagnostic molecular test. It uniquel

      4/24/25 4:00:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

       ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels     PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024. Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full Year resulting in double-digit Q4 and YTD revenue growth. "The Company achieved record test volume, test revenue, income, and cash collections in Q4 and full year 2024," said Chris McCarthy, Chief Financial Office

      1/31/25 8:30:00 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Financials

    Live finance-specific insights

    See more
    • Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

       ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper

      5/16/22 4:15:00 PM ET
      $IDXG
      $TWST
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

       ●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace

      11/10/21 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results

       ●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter  ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin

      8/10/21 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccarthy Christopher converted options into 38,475 shares, increasing direct ownership by 463% to 46,791 units (SEC Form 4)

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      4/25/25 4:18:01 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner 1315 Capital Ii, L.P.

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      10/15/24 7:00:31 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Ampersand 2018 Limited Partnership

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      10/15/24 7:00:05 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

      SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      10/16/24 4:35:44 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

      SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      10/16/24 4:30:56 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Interpace Biosciences, Inc. (Amendment)

      SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      2/12/24 5:01:48 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Leadership Updates

    Live Leadership Updates

    See more
    • Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

       ●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year  ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million  PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. "2021 has been a transformative year for Interpace," said Thomas Burnell, President and CEO. Burnell added, "The Company e

      3/31/22 4:15:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

      PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in

      1/27/22 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care